EP4174092A4 - MULTI-SPECIFIC IMMUNE CELL RECRUITER BINDING PROTEIN, PREPARATION AND USE THEREOF - Google Patents

MULTI-SPECIFIC IMMUNE CELL RECRUITER BINDING PROTEIN, PREPARATION AND USE THEREOF Download PDF

Info

Publication number
EP4174092A4
EP4174092A4 EP21833675.8A EP21833675A EP4174092A4 EP 4174092 A4 EP4174092 A4 EP 4174092A4 EP 21833675 A EP21833675 A EP 21833675A EP 4174092 A4 EP4174092 A4 EP 4174092A4
Authority
EP
European Patent Office
Prior art keywords
preparation
binding protein
immune cell
specific immune
recruiter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21833675.8A
Other languages
German (de)
French (fr)
Other versions
EP4174092A1 (en
Inventor
Yun He
Lei Shi
Xiaodong Wu
Chen ZHONG
Bing Huang
Yiping Rong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nona Biosciences Shanghai Co Ltd
Original Assignee
Harbour Biomed Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbour Biomed Shanghai Co Ltd filed Critical Harbour Biomed Shanghai Co Ltd
Publication of EP4174092A1 publication Critical patent/EP4174092A1/en
Publication of EP4174092A4 publication Critical patent/EP4174092A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21833675.8A 2020-06-30 2021-06-29 MULTI-SPECIFIC IMMUNE CELL RECRUITER BINDING PROTEIN, PREPARATION AND USE THEREOF Pending EP4174092A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010630471 2020-06-30
PCT/CN2021/103065 WO2022002038A1 (en) 2020-06-30 2021-06-29 Multispecific binding protein of immune cell engager, preparation therefor and application thereof

Publications (2)

Publication Number Publication Date
EP4174092A1 EP4174092A1 (en) 2023-05-03
EP4174092A4 true EP4174092A4 (en) 2024-03-20

Family

ID=79317489

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21833675.8A Pending EP4174092A4 (en) 2020-06-30 2021-06-29 MULTI-SPECIFIC IMMUNE CELL RECRUITER BINDING PROTEIN, PREPARATION AND USE THEREOF

Country Status (5)

Country Link
US (1) US20230303698A1 (en)
EP (1) EP4174092A4 (en)
CN (1) CN115698088A (en)
TW (1) TWI806087B (en)
WO (1) WO2022002038A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115667316A (en) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Binding proteins of Fab-HCAb structure
TWI833244B (en) * 2021-06-18 2024-02-21 大陸商和鉑醫藥（上海）有限責任公司 A dual-antibody combination and its application
WO2023174521A1 (en) * 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
JP2025541438A (en) * 2022-12-19 2025-12-18 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド "κ/λ" Fab-Fab tandem multispecific binding protein and its production and application
CN116284419B (en) * 2023-02-07 2024-10-11 深圳市先康达生命科学有限公司 Monoclonal antibodies targeting human GUCY2C protein and their applications
WO2025051229A1 (en) * 2023-09-08 2025-03-13 北京拓界生物医药科技有限公司 Igf-1r and tshr binding protein and pharmaceutical use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120316324A1 (en) * 2009-09-25 2012-12-13 Ucb Pharma, S.A. Disulfide Stabilised Multivalent Antibodies
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
CN110627906A (en) * 2019-10-10 2019-12-31 上海洛启生物医药技术有限公司 Anti-PD-L1/4-1BB bispecific antibody and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI404727B (en) 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 Dual gene exclusion
CA2898100C (en) * 2013-01-14 2023-10-10 Xencor, Inc. Novel heterodimeric proteins
BR112016015140A2 (en) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. tandem-fab immunoglobulin and its uses
EP3307776A1 (en) * 2015-06-15 2018-04-18 Numab Innovation AG Hetero-dimeric multi-specific antibody format
NZ777930A (en) * 2015-07-16 2025-05-02 Inhibrx Biosciences Inc Multivalent and multispecific dr5-binding fusion proteins
EP3573997A4 (en) * 2017-01-24 2020-12-09 Abexxa Biologics, Inc. METHOD AND COMPOSITIONS FOR TARGETING A COMPLEX NOT INCLUDING CLASSIC HLA-I AND NEOANTIGEN IN CANCER
WO2019184909A1 (en) * 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 Novel antibody molecule, and preparation method and use thereof
CN111902428B (en) * 2018-07-03 2023-11-10 上海健信生物医药科技有限公司 A bispecific antibody and its use
CA3115082A1 (en) * 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
CA3118397A1 (en) * 2018-11-01 2020-05-07 Shandong Newtime Pharmaceutical Co., Ltd. Bispecific antibody targeting cd3 and bcma, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407513B2 (en) * 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
US20120316324A1 (en) * 2009-09-25 2012-12-13 Ucb Pharma, S.A. Disulfide Stabilised Multivalent Antibodies
CN110627906A (en) * 2019-10-10 2019-12-31 上海洛启生物医药技术有限公司 Anti-PD-L1/4-1BB bispecific antibody and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRINKMANN ULRICH ET AL: "The making of bispecific antibodies", MABS, vol. 9, no. 2, 17 February 2017 (2017-02-17), US, pages 182 - 212, XP093126617, ISSN: 1942-0862, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297537/pdf/kmab-09-02-1268307.pdf> DOI: 10.1080/19420862.2016.1268307 *
GEOFFREY L FRANCIS: "Albumin and mammalian cell culture: implications for biotechnology applications", CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 62, no. 1, 6 April 2010 (2010-04-06), pages 1 - 16, XP019788290, ISSN: 1573-0778 *
See also references of WO2022002038A1 *

Also Published As

Publication number Publication date
TWI806087B (en) 2023-06-21
TW202202524A (en) 2022-01-16
WO2022002038A1 (en) 2022-01-06
EP4174092A1 (en) 2023-05-03
CN115698088A (en) 2023-02-03
US20230303698A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
EP4174092A4 (en) MULTI-SPECIFIC IMMUNE CELL RECRUITER BINDING PROTEIN, PREPARATION AND USE THEREOF
EP3833386A4 (en) MULTI-SPECIFIC BINDING PROTEINS BINDING TO HER2, NKG2D, AND CD16, AND METHODS OF USE
EP3833392A4 (en) MULTI-SPECIFIC BINDING PROTEINS BINDING TO BCMA, NKG2D AND CD16, AND METHODS OF USE
DK1356052T3 (en) Production of whole antibodies in prokaryotic cells
EP3802617A4 (en) MULTI-SPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF
EP3735458A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
EP3824096A4 (en) NOVEL ANTIBODIES AND METHODS FOR THE PREPARATION AND USE THEREOF
EP4289861A4 (en) ANTIBODIES AGAINST HUMAN TSLP AND THEIR USE
BR112019002127A2 (en) fusion protein, vector, cell, pharmaceutical composition, and fusion protein use
EP4408896A4 (en) NKG2D, CD16 AND BAFF-R BINDING PROTEINS
EA201000424A1 (en) ANTIBODIES TO IL-23
EP4212019A4 (en) ALGINATE DI-OLIGOSACCHARIDE PROTEIN COMPOSITION, PREPARATION METHOD THEREOF AND USE THEREOF
EP4063497A4 (en) ANTI-IMP TYPE CARBAPENEMASE HYBRIDOME CELL STEM, MONOCLONAL ANTIBODY AND USE
CL2012001030A1 (en) Immunomodulatory polypeptide derived from il-2 comprising several mutations to the native il-2 sequence that preferentially inhibits the activity of il-2 on regulatory t cells in vitro; fusion protein comprising it; and its use to treat cancer.
EP4349979A4 (en) MODIFIED CAS12I NUCLEASE, EFFECTOR PROTEIN AND USE THEREOF
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
WO2020169755A3 (en) Antibodies
EP3994275A4 (en) RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
EP4061729A4 (en) STACKABLE CARTONS, SYSTEM, AND METHODS OF USE
EP4426321A4 (en) Immune cell populations and uses thereof
EP3946354A4 (en) HETEROMULTIMER PROTEINS AND THEIR METHODS OF USE
EP3980067A4 (en) ANTIBODY-INTERLEUKIN FUSION PROTEIN AND METHODS OF USE
EP4253414A4 (en) ANTI-TIGIT ANTIBODIES, PHARMACEUTICAL COMPOSITION AND CORRESPONDING USE
MA52141A (en) VETERINARY COMPOSITION CONSISTING OF SUPEROXIDE DISMUTASE AND AT LEAST ONE PROTEIN HYDROLYSATE RICH IN BIOASSIMILABLE PEPTIDES
EP4265717A4 (en) MOUSE ANTI-MCR-1/MCR-2 PROTEIN HYBRIDOMA CELL STRAIN, MONOCLONAL ANTIBODY AND USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

A4 Supplementary search report drawn up and despatched

Effective date: 20240221

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/30 20060101ALI20240215BHEP

Ipc: C07K 16/32 20060101ALI20240215BHEP

Ipc: A61K 39/00 20060101ALI20240215BHEP

Ipc: C07K 16/28 20060101ALI20240215BHEP

Ipc: A61P 35/00 20060101ALI20240215BHEP

Ipc: A61K 39/395 20060101ALI20240215BHEP

Ipc: C12N 15/13 20060101ALI20240215BHEP

Ipc: C07K 16/46 20060101AFI20240215BHEP

17Q First examination report despatched

Effective date: 20240304

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NONA BIOSCIENCES (SHANGHAI) CO., LTD